Overview
- Pharmarack data show Eli Lilly’s tirzepatide brand booked ₹100 crore ($11.38 million) in October, topping monthly sales by value and overtaking GSK’s Augmentin, which logged ₹80 crore.
- Mounjaro has generated about ₹333 crore in cumulative sales since its late‑March launch, rapidly scaling India’s nascent anti‑obesity segment.
- Usage was roughly ten times higher than Novo Nordisk’s Wegovy by volume in October, with sales clusters identified in affluent Mumbai areas such as Juhu, Andheri (West), Colaba and Worli.
- Lilly has moved to expand reach through a Cipla collaboration that will distribute tirzepatide under a second brand, Yurpeak, with monthly patient costs reported between ₹14,000 and ₹27,500 depending on dose.
- Analysts point to a near‑term shakeup as semaglutide patents expire in India next March and branded generics are expected to enter, while BusinessLine reports White House‑level commitments by Lilly and Novo to MFN‑style global price cuts.